Cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are a few symptoms of cardiometabolic diseases. Individuals suffering from cardiometabolic syndrome are prone to many other life-threatening diseases, such as type 2 diabetes, stroke, coronary artery disease (CAD), and cardiovascular disease (CVD). Both genetic and environmental conditions are responsible for the development of the diseases.
This report contains market size and forecasts of Cardiometabolic Diseases in Global, including the following market information:
Global Cardiometabolic Diseases Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Cardiometabolic Diseases market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
ACE Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Cardiometabolic Diseases include Eli Lilly and Company, Bayer AG, Arrowhead Pharmaceuticals, Inc, Novartis AG, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, AstraZeneca, Alnylam Pharmaceuticals, Inc. and Cardax, Inc and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cardiometabolic Diseases companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cardiometabolic Diseases Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Cardiometabolic Diseases Market Segment Percentages, by Type, 2021 (%)
ACE Inhibitors
Diuretics
Glucophage
Others
Global Cardiometabolic Diseases Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Cardiometabolic Diseases Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Cardiometabolic Diseases Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Cardiometabolic Diseases Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cardiometabolic Diseases revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Cardiometabolic Diseases revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly and Company
Bayer AG
Arrowhead Pharmaceuticals, Inc
Novartis AG
Boehringer Ingelheim International GmbH
Novo Nordisk A/S
AstraZeneca
Alnylam Pharmaceuticals, Inc.
Cardax, Inc
Kowa Company, Ltd.